prof. dr. Fritz Offner
- Work address
-
C. Heymanslaan 10, ingang 12 - verdieping 6
9000 Gent - Fritz.Offner@UGent.be
- ORCID iD
-
0000-0003-4690-3603
Show
Sort by
-
- Journal Article
- A1
- open access
Real-world estimation of first- and second-line treatments for diffuse large B-cell lymphoma using health insurance data : a Belgian population-based study
-
Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma
-
Cusatuzumab for treatment of CD70-positive relapsed or refractory cutaneous T-cell lymphoma
-
Comparison of the effectiveness and safety of the oral selective inhibitor of nuclear export, selinexor, in diffuse large B cell lymphoma subtypes
-
- Journal Article
- A1
- open access
Prolonged remissions after nivolumab plus gemcitabine/oxaliplatin in relapsed/refractory T-cell lymphoma
-
Identifying patients with chronic lymphocytic leukemia without need of treatment : end of endless watch and wait?
-
Systemic mastocytosis with myeloid sarcoma and B-CLL : molecular and clonal heterogeneity in a rare case of SM-AHN with review of literature
-
- Journal Article
- A1
- open access
Shallow-depth sequencing of cell-free DNA for Hodgkin and diffuse large B-cell lymphoma (differential) diagnosis : a standardized approach with underappreciated potential
-
Up to seven years of follow-up in the RESONATE-2 study of first-line ibrutinib treatment for patients with chronic lymphocytic leukemia
-
- Journal Article
- A1
- open access
Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma : a phase I trial